Reading NVST? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track NVST free→Reading NVST? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track NVST free→NYSEHealth CareMedical Instruments & SuppliesSnapshot 2026-06-15
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is strong, and earnings quality is robust, cash backs up reported profits. Management's recent track record has been steady, and it has a capital-friendly stance. However, the sector backdrop is a headwind, and risk is moderate. Peer multiples imply a price about 11% above where it trades (it looks cheap on this basis); the read is fair, quality intact. This assessment is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 7 valuation methods, at three horizons. Current price $24.68. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $25 NVST trades at 19× p/e, below its 20× p/e peer median. Our $28 fair value sits above the price; medium confidence. Analysts: $30–$33. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 11% below a flat-multiple fair value, below our forecast of about 10%. This describes what's priced in, not a forecast of the move.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
Over the trailing year it converted 4.02x of net income into operating cash flow. Historically, Health Care names rated robust grew net income 60% of the time over the next year (vs 48% for the rest of the cohort, n=1703).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $0.33 → $0.34 (+0.4% / 30d). 7 raised, 3 cut, 14 covering analysts.
0 upgrades, 0 downgrades / 30d, 1 maintained. 47% of analysts rate Buy.
1 PT revisions / 30d. Avg target 33.0% above current price.
0 positive, 0 negative / 30d.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$139.
How much price usually moves either way.
On a bad day, this stock has moved -$320.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $2,597.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
Confidence changed from 'high' to 'medium'.
As of June 15, 2026, confidence changed to medium. Risk fell, indicating a moderate level of uncertainty. The sector backdrop remains a headwind, suggesting challenges in the broader market environment. Valuation is described as expensive, reflecting a higher price relative to earnings compared to peers.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: This would signal a slowdown in revenue growth, which is critical for Envista's performance.
Confirms:Q2 core sales growth reported below 2%.
Disproves:Q2 core sales growth reported above 4%.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for NVST yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS On May 28, 2026, Faez Kaabi notified Envista Holdings Corporation (the “Company”) of his intention to resign as Chief Accounting Officer and principal accounting officer of the Company effective as of August 6, 2026. Mr. Kaabi’s resignation is in connection with his retirement and not the result of any disagreement with the Company regarding financi…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
$30.00 – $33.00 (median $31.50) · 4 analysts · as of 2026-06-11
Roughly priced in line with peers.
Around its own typical valuation.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Health Care Supplies.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
NVST Envista Holdings | Above typical Show detailsSector percentile: 93 of 100 | fair | moderate |
MDLN MEDLINE INC | — | full | moderate |
WST West Pharmaceutical Services | Above typical Show detailsSector percentile: 94 of 100 | expensive | moderate |
COO Cooper Companies (The) | Above typical Show detailsSector percentile: 74 of 100 | fair | moderate |
ALGN Align Technology | Above typical Show detailsSector percentile: 94 of 100 | fair | elevated |
1 material management or governance event in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 56% of the time over the next year (vs 52% for the rest of the cohort, n=618).
Not investment advice. As of 2026-06-15.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Focus on increasing revenue growth through core sales expansion.
Enhance operating income through cost management and efficiency improvements.
Focus on improving cash flow from operations to support financial stability.
Why it matters: This shows that Envista is having trouble increasing its operating income. This affects profits.
Confirms:Adjusted EBITDA growth is below 7%.
Disproves:Adjusted EBITDA growth is above 13%.
Why it matters: A drop in sector revenue growth could signal broader challenges. This affects Envista's growth outlook.
Confirms:Sector revenue growth falls below its median rate.
Disproves:Sector revenue growth remains steady or improves.
Why it matters: Improving operating income would show progress in cost management. This is crucial for long-term growth.
Confirms:Operating income is higher than last quarter.
Disproves:Operating income goes down or stays the same from last quarter.
Why it matters: Improved cash flow is crucial for Envista to support its growth and investment plans.
Confirms:Operating cash flow turns positive for Q2 2026.
Disproves:Operating cash flow remains negative for Q2 2026.
RESULTS OF OPERATIONS AND FINANCIAL CONDITION On May 6, 2026, Envista Holdings Corporation (“Envista” or the “ Company”) issued a press release announcing financial results for the quarter ended April 3, 2026. A copy of the release is furnished herewith as Exhibit 99.1 and incorporated by reference herein. The information contained in the accompanying Exhibit 99.1 is being furnished pursuant to
RESULTS OF OPERATIONS AND FINANCIAL CONDITION On February 5, 2026, Envista Holdings Corporation (“Envista” or the “ Company”) issued a press release announcing financial results for the quarter ended December 31, 2025. A copy of the release is furnished herewith as Exhibit 99.1 and incorporated by reference herein. The information contained in the accompanying Exhibit 99.1 is being furnished pursuant to